Masimo Corp
NASDAQ:MASI
Operating Margin
Masimo Corp
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Operating Margin Across Competitors
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| US |
|
Masimo Corp
NASDAQ:MASI
|
9B USD |
4%
|
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
230.3B USD |
17%
|
|
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
182.6B USD |
28%
|
|
| US |
|
Boston Scientific Corp
NYSE:BSX
|
149.8B USD |
19%
|
|
| US |
|
Stryker Corp
NYSE:SYK
|
143.5B USD |
22%
|
|
| IE |
|
Medtronic PLC
NYSE:MDT
|
110.7B USD |
20%
|
|
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
51.8B EUR |
14%
|
|
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
48.3B USD |
13%
|
|
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
43.5B USD |
28%
|
|
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
42.3B USD |
29%
|
|
| CN |
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
275.5B CNY |
34%
|
Masimo Corp
Glance View
Masimo Corp., a pioneering force in noninvasive monitoring technologies, was founded in 1989 by Joe Kiani, who envisioned a healthcare landscape imbued with precision and accessibility. The company rose to prominence with its innovative pulse oximetry technology, a tool crucial for measuring oxygen levels in patients' blood. Unlike traditional methods, Masimo's technology utilizes proprietary signal extraction techniques that allow it to deliver accurate readings even in challenging conditions such as movement or low perfusion. This innovation not only revolutionized patient monitoring but also secured Masimo significant market share within hospitals and healthcare facilities worldwide. Their devices, known for their reliability, feed into a recurring revenue model, as hospitals and medical professionals constantly require new sensors and related consumables to operate the equipment effectively. In addition to pulse oximetry, Masimo has skillfully expanded its portfolio to encompass advanced monitoring systems such as those measuring brain function and hydration levels, offering a comprehensive suite of solutions for enhanced patient care. They have ventured into consumer health as well, with devices that allow people to monitor their health metrics at home. This broadening of scope positions Masimo as a versatile player across both professional and consumer markets. By continually investing in research and development, Masimo aims to address unmet clinical needs and open new revenue streams, thus sustaining its growth trajectory in the competitive landscape of medical technology. Through strategic partnerships and acquisitions, the company has consistently augmented its capabilities, solidifying a robust financial performance anchored in its commitment to innovation and quality.
See Also
Operating Margin represents how efficiently a company is able to generate profit through its core operations.
Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.
Based on Masimo Corp's most recent financial statements, the company has Operating Margin of 4.2%.
You don't have any saved screeners yet